21 CFR 211.68(b)
Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.68(b): the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR 211.68(b)?
- 2 DSRV articles cite 21 CFR 211.68(b). Enforcement cases behind them: FDA Warning Letter 320-24-62, CMS Case 684644, to MMC Healthcare Ltd., September 24, 2024; FDA data integrity warning letters to Sun Pharmaceutical, Ipca Laboratories, and Hetero Drugs, read against FDA's guidance for industry, Data Integrity and Compliance With Drug CGMP: Questions and Answers, December 2018. Inspection exposure across them: 2 high.
- What does DSRV recommend for 21 CFR 211.68(b)?
- From the newest article (FDA Data Integrity Violations Keep Repeating. This Is Why.): The decisive control is whether the quality unit actively monitors what the data environment is producing, because computerized system controls that rest on the assumption that personnel are honest are not a defensible position under 21 CFR 211.68(b). DSRV is decision support, not legal advice; verify against the official source each article names.
- 5 min readHigh exposure
FDA Data Integrity Violations Keep Repeating. This Is Why.
FDA has cited data integrity failures under 21 CFR 211.68(b) for years, and recent warning letters against MMC Healthcare and Landy International follow the same pattern. The violation is never really about the data system.
- Case
- FDA Warning Letter 320-24-62, CMS Case 684644, to MMC Healthcare Ltd., September 24, 2024.
- DSRV take
- The decisive control is whether the quality unit actively monitors what the data environment is producing, because computerized system controls that rest on the assumption that personnel are honest are not a defensible position under 21 CFR 211.68(b).
- 7 min readHigh exposure
FDA Data Integrity Enforcement Is Accelerating — Here's What the Warning Letters Actually Say
Data integrity citations appeared in over 60% of pharmaceutical manufacturing warning letters in 2025. FDA is citing the systems that allowed falsification to happen unchallenged — not just the falsification itself. Here is what the enforcement record shows and what separates sites that pass from those that don't.
- Case
- FDA data integrity warning letters to Sun Pharmaceutical, Ipca Laboratories, and Hetero Drugs, read against FDA's guidance for industry, Data Integrity and Compliance With Drug CGMP: Questions and Answers, December 2018.
- DSRV take
- The separating control is whether audit trail review, OOS-rate trending, and validated technical access controls run as scheduled operations, because FDA reads an undetected manipulation pattern as a failed quality system rather than an analyst problem.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR 211.68(b). DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.